RE:RE:RE:RE:RE:RE:RE:ZenithJK wrote: "ThANKS AGAIN BEAR! WILL THOSE OF US HOLDING ZENITH UNITS HAVE ANY EXPECTATION OF RECEIVING ANY BENEFIT VIS THE RPS’s?"
Great question JK. As RVXoldtimer wrote "With Apabetalone success, the Royalty Preferred Shares could become very valuable. Even though it is ZCC that owns them and not us, we own ZCC. At the split, RVX owners received a proportinate share of Zenith (now ZCC) shares and even with some dilution to financings still own a subtantial percentage of ZCC. Royalty payments to ZCC boost the value of your ZCC shares. The royalties can stay in ZCC to use on research, trials, etc. and fend off future dilution or be dividended out to ZCC shareholders."
I would agree with what RVXoldtimer wrote except to clarify that the money from the RPSs flows directly to Zenith Capital Corp not Zenith Epigenetics Ltd. Shareholders of Zenith Capital Corp will be the indirect beneficiaries of these RPSs and may potentially receive a divident payment at the discretion of Zenith Capital Corp management/board of directors. However, as far as I recall there has been no explicit statement that dividends to shareholders will be issued. This will be a great issue to discuss IF and WHEN BETonMACE succeeds since the holder of Royalty Preferred Shares (ZCC) is entitled to a dividend calculated based on a percentage of net revenue earned from the sale or licensing of ANY pharmaceutical product in which Resverlogic holds an intellectual property right.
BDAZ